Why the study?
Primary viral myocarditis associated with SARS-CoV-2 is rare, and an overview of therapeutic options for patients with COVID-19-associated myocarditis is needed.
Does mechanical circulatory support (VA-ECMO and Impella) improve survival and cardiac recovery in patients with severe COVID-19-associated myocarditis with cardiogenic shock?
Does mechanical circulatory support (VA-ECMO and Impella) improve survival and cardiac recovery in patients with severe COVID-19-associated myocarditis with cardiogenic shock?
Immediate invasive bridging therapy with mechanical circulatory support (VA-ECMO and Impella) can be lifesaving and lead to rapid cardiac recovery in patients with fulminant cardiogenic shock due to COVID-19-associated myocarditis.
Answers are grounded in this paper and cite their sources.
Supports feasibility of combined VA-ECMO and Impella in COVID-19 myocarditis shock; hypothesis-generating, should not yet change practice.
BACKGROUND: Primary viral myocarditis associated with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) infection is a rare diagnosis. CASE PRESENTATION: We report the case of an unvaccinated, healthy patient with cardiogenic shock in the context of a COVID-19-associated myocarditis and therapy with simultaneous veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and percutaneous left ventricular decompression therapy with an Impella. The aim of this review is to provide an overview of therapeutic options for patients with COVID-19-associated myocarditis. CONCLUSIONS: The majority of patients required a combination of two assist devices to achieve sufficient cardiac output until recovery of left ventricular ejection fraction. Due to the rapid onset of this fulminant cardiogenic shock immediate invasive bridging therapy in a specialized center was lifesaving.
No takes yet. Share an insight, caveat, or question.
Noone et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: